News|Articles|February 19, 2025
Executive Summary: Accelerating High-Titer Expression for Complex Next-Gen Biologics
Author(s)Catalent
The right cell line development technology can address production challenges associated with expression and scalability of complex biologics.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina
2
Generative AI and Adaptive Trials Shape Future Biotech Development
3
How FDA’s Bayesian Guidance Could Accelerate Adaptive Trial Design in Biopharmaceuticals
4
Why Biotech’s Clinical Maturity Is Driving New Partnerships and Capacity Plays
5